| Dr John V Selthafner, MD | |
|
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
| (414) 805-8700 | |
| (414) 259-1522 |
| Full Name | Dr John V Selthafner |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 36 Years |
| Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013024207 | NPI | - | NPPES |
| 1013024207 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 31385-020 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
News Archive
Approximately one third of all brain aneurysms rupture during a patient's lifetime, resulting in a brain haemorrhage. A recent Finnish study demonstrates that, unlike what was previously assumed, the size of the aneurysm does not significantly impact the risk of rupture.
Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.
Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.
Cell biologists led by Thomas Maresca at the University of Massachusetts Amherst, with collaborators elsewhere, report an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.
› Verified 1 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Approximately one third of all brain aneurysms rupture during a patient's lifetime, resulting in a brain haemorrhage. A recent Finnish study demonstrates that, unlike what was previously assumed, the size of the aneurysm does not significantly impact the risk of rupture.
Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.
Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.
Cell biologists led by Thomas Maresca at the University of Massachusetts Amherst, with collaborators elsewhere, report an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.
› Verified 1 days ago
| Entity Name | Watertown Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770964363 PECOS PAC ID: 8022329408 Enrollment ID: O20150626000114 |
News Archive
Approximately one third of all brain aneurysms rupture during a patient's lifetime, resulting in a brain haemorrhage. A recent Finnish study demonstrates that, unlike what was previously assumed, the size of the aneurysm does not significantly impact the risk of rupture.
Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.
Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.
Cell biologists led by Thomas Maresca at the University of Massachusetts Amherst, with collaborators elsewhere, report an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John V Selthafner, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-8700 | Dr John V Selthafner, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-8700 |
News Archive
Approximately one third of all brain aneurysms rupture during a patient's lifetime, resulting in a brain haemorrhage. A recent Finnish study demonstrates that, unlike what was previously assumed, the size of the aneurysm does not significantly impact the risk of rupture.
Scientists at Scripps Research have discovered the role of an immune system double agent. This molecule, called USP18, can help curtail immune responses, but it can also open the door to bacterial infections, such as harmful listeria and staph infections.
Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease.
Cell biologists led by Thomas Maresca at the University of Massachusetts Amherst, with collaborators elsewhere, report an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
Bend Research Inc., a leading independent drug-formulation development and manufacturing company, today announced a licensing agreement with Affinium Pharmaceuticals, Ltd.
› Verified 1 days ago
Dr. Jeffrey T Lyvers, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2900 W Oklahoma Ave, Milwaukee, WI 53215 Phone: 414-649-6000 | |
Dr. Nosheen Hasan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7235 W Appleton Ave, Sutie 102, Milwaukee, WI 53216 Phone: 414-444-8670 Fax: 414-444-8678 | |
Dr. Quinn Hogan, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 9200 W Wisconsin Ave, Department Of Anesthesiology, Milwaukee, WI 53226 Phone: 414-805-8700 Fax: 414-259-1522 | |
Dr. Stephen R Thompson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2025 E Newport Ave, Milwaukee, WI 53211 Phone: 414-961-3300 | |
Dr. Christina D Diaz, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 9200 W Wisconsin Ave, Department Of Anesthesiology, Milwaukee, WI 53226 Phone: 414-805-8700 Fax: 414-259-1522 | |
Anne M Fagan, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10200 W Innovation Dr, Milwaukee, WI 53226 Phone: 414-302-9196 |